Cargando…

The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC

Although immune checkpoint and targeted therapies offer remarkable benefits for lung cancer treatment, some patients do not qualify for these regimens or do not exhibit consistent benefit. Provided that lung cancer appears to be driven by transforming growth factor beta signaling, we investigated th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marwitz, Sebastian, Turkowski, Kati, Nitschkowski, Dörte, Weigert, Andreas, Brandenburg, Julius, Reiling, Norbert, Thomas, Michael, Reck, Martin, Drömann, Daniel, Seeger, Werner, Rabe, Klaus F., Savai, Rajkumar, Goldmann, Torsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985561/ https://www.ncbi.nlm.nih.gov/pubmed/32039023 http://dx.doi.org/10.3389/fonc.2019.01550

Ejemplares similares

Live and let die: epigenetic modifications of Survivin and Regucalcin in non-small cell lung cancer tissues contribute to malignancy
por: Nitschkowski, Dörte, et al.
Publicado: (2019)

Haemophilus influenzae causes cellular trans-differentiation in human bronchial epithelia
por: Glöckner, Michael, et al.
Publicado: (2021)

Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy
por: Zheng, Xiang, et al.
Publicado: (2017)

Epigenetic modifications of the VGF gene in human non-small cell lung cancer tissues pave the way towards enhanced expression
por: Marwitz, Sebastian, et al.
Publicado: (2017)

Human alveolar epithelial cells type II are capable of TGFβ-dependent epithelial-mesenchymal-transition and collagen-synthesis
por: Goldmann, Torsten, et al.
Publicado: (2018)

DNA methylation profiles of bronchoscopic biopsies for the diagnosis of lung cancer
por: Goldmann, Torsten, et al.
Publicado: (2021)

Therapeutical Administration of Peptide Pep19-2.5 and Ibuprofen Reduces Inflammation and Prevents Lethal Sepsis
por: Heinbockel, Lena, et al.
Publicado: (2015)

Phosphorylation of SMAD3 in immune cells predicts survival of patients with early stage non-small cell lung cancer
por: Marwitz, Sebastian, et al.
Publicado: (2021)

Role and New Insights of Pirfenidone in Fibrotic Diseases
por: Lopez-de la Mora, David Alejandro, et al.
Publicado: (2015)

Fibroblast Growth Factor—14 Acts as Tumor Suppressor in Lung Adenocarcinomas
por: Turkowski, Kati, et al.
Publicado: (2020)

Fountain of youth for squamous cell carcinomas? On the epigenetic age of non‐small cell lung cancer and corresponding tumor‐free lung tissues
por: Marwitz, Sebastian, et al.
Publicado: (2018)

Anti-fibrotic action of pirfenidone in Dupuytren’s disease-derived fibroblasts
por: Zhou, Chaoming, et al.
Publicado: (2016)

Interferon Regulatory Factor 9 Promotes Lung Cancer Progression via Regulation of Versican
por: Brunn, David, et al.
Publicado: (2021)

Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression
por: Marwitz, Sebastian, et al.
Publicado: (2017)

Fibrocytes boost tumor-supportive phenotypic switches in the lung cancer niche via the endothelin system
por: Weigert, Andreas, et al.
Publicado: (2022)

Endotoxin induces proliferation of NSCLC in vitro and in vivo: role of COX-2 and EGFR activation
por: Hattar, Katja, et al.
Publicado: (2012)

Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation
por: Ballester, Beatriz, et al.
Publicado: (2020)

Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone
por: Ma, Hsiao-Yen, et al.
Publicado: (2023)

Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1
por: Jin, Jin, et al.
Publicado: (2019)

Pressure overload induced right ventricular remodeling is not attenuated by the anti-fibrotic agent pirfenidone
por: Andersen, Stine, et al.
Publicado: (2019)

PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung
por: Goldmann, Torsten, et al.
Publicado: (2021)

The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts
por: Mediavilla-Varela, Melanie, et al.
Publicado: (2016)

Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
por: Molina-Molina, M., et al.
Publicado: (2018)

The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1
por: Xi, Yue, et al.
Publicado: (2021)

Pirfenidone Has Anti-fibrotic Effects in a Tissue-Engineered Model of Human Cardiac Fibrosis
por: Bracco Gartner, Thomas C. L., et al.
Publicado: (2022)

Exposomes to Exosomes: Exosomes as Tools to Study Epigenetic Adaptive Mechanisms in High-Altitude Humans
por: Padmasekar, Manju, et al.
Publicado: (2021)

Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC
por: Gaber, Rania, et al.
Publicado: (2014)

The Wnt Blows: On the Functional Role of Wnt Signaling in Mycobacterium tuberculosis Infection and Beyond
por: Brandenburg, Julius, et al.
Publicado: (2016)

A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases
por: Shah, Parth V, et al.
Publicado: (2021)

Picturing of the Lung Tumor Cellular Composition by Multispectral Flow Cytometry
por: Olesch, Catherine, et al.
Publicado: (2022)

Pirfenidone attenuates synovial fibrosis and postpones the progression of osteoarthritis by anti-fibrotic and anti-inflammatory properties in vivo and in vitro
por: Wei, Qilu, et al.
Publicado: (2021)

Design and rationale of a randomised, double-blind trial of the efficacy and safety of pirfenidone in patients with fibrotic hypersensitivity pneumonitis
por: Fernández Pérez, Evans R., et al.
Publicado: (2021)

The TGF-beta-Pseudoreceptor BAMBI is strongly expressed in COPD lungs and regulated by nontypeable Haemophilus influenzae
por: Drömann, Daniel, et al.
Publicado: (2010)

Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma
por: Banat, G-Andre, et al.
Publicado: (2015)

Correction to: Pirfenidone attenuates synovial fibrosis and postpones the progression of osteoarthritis by anti-fibrotic and anti-inflammatory properties in vivo and in vitro
por: Wei, Qilu, et al.
Publicado: (2021)

The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?
por: Ferrara, Francesco, et al.
Publicado: (2020)

Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC
por: Cekay, Michael, et al.
Publicado: (2023)

Pirfenidone: is it tolerable?
por: Lara, Abigail, et al.
Publicado: (2016)

Pirfenidone, an Anti-Fibrotic Drug, Suppresses the Growth of Human Prostate Cancer Cells by Inducing G(1) Cell Cycle Arrest
por: Ishii, Kenichiro, et al.
Publicado: (2019)

The in vitro anti-fibrotic effect of Pirfenidone on human pterygium fibroblasts is associated with down-regulation of autocrine TGF-β and MMP-1
por: Tao, Yijin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3st3jlhqktpgpur9lh0tvjvv6r